Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/739,208

Filing Date December 18, 2003

First Named Inventor KUZMICH, D., et al

Art Unit 1614

Examiner Name To be Assigned

(Use as many sheets as necessary)

Substitute for form 1449A/PTO

Sheet 1 of 5 Attorney Docket Number 9/272

Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (Fiscond)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Retevant Passages or Relevant Figures Appear
MS		US- 6,323,199	11/27/2001	Lehmann, M. et al	
M		US- 5,039,691	08//13/1999	Spagnuolo, C. et al	***************************************
MS		US- 6,583,180	06/24/2003	Link, J.T. et al	
M		US- 6,329,534	12/11/2001	Kym, P.R. et al	
		US- 6,436,986	08/20/2003	Kym, P.R. et al	
		^{US-} 4,880,839	11/14/1999	Tucker, H.	
		US- 2002/0156311	10/24/2002	Link, J.T. et al	
		^{US-} 6,506,766	01/14/2003	Coghlan, M.J. et al	
		^{US-} 6,380,223	04/30/2002	Dow, R.L., et al	
		US- 2003/0232823 A1	12/18/2003	Betageri, R., et al	
		US-2004/0097574 A1	05/20/2004	Marshail, D.R.	
		^{US-} 2004/0010148 A1	01/15/2004	Kirrane, T.M., Jr. et al	
		^{US-} 2004/0010020 A1	01/15/2004	Kirrane, T.M., Jr., et al	
V		^{US-} 2004/0029932 A1	02/12/2004	Bekkali, Y., et al	
MS		^{US-} 2002/0077356 A1	06/20/2002	Jaroch, S., et al	
		US-			
		US-			
		· US-		1	

		FOREIG	N PATENT DOC	JMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	_
Initials*	No.'	Country Code ³ 'Number ⁴ 'Kind Code ⁵ (# known)	MM-DO-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
8.5		WO 02/10143	02/07/2002	Schering Aktiengesel.		
1		WO 02064550	08/22/2002	Abbott Laboratories		
	***************************************	WO 99/41256	02/12/1999	Abbott Laboratories		
V	*********	WO 02/02565	01/10/2002	Abbott Laboratories		
MS		WO 00/66522	11/09/2000	Pfizer Products, Inc		

Examiner Signature	/D Margaret Seaman/	• Date Considered	05/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPO Patent Documents at www.usr/o.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

I ransation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (06-03)

Approved for use through 07/31/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number. Under the Panerwork Reduction Act of 1995, no persons are required to resp Complete if Known Substitute for form 1449A/PTO Application Number 10/739,208 Filing Date INFORMATION DISCLOSURE December 18, 2003 First Named Inventor KUZMICH, Daniel, et al. STATEMENT BY APPLICANT Art Unit 1614 Examiner Name To be assigned (Use as many sheets as necessary) Attorney Docket Number 9/272 5 Sheet

Examiner	Cite No.1	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.¹	Number-Kind Code ² (Finous)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		U\$-			
	-	US-			
		US-			
	"	US-			
		US-			
		US-			
		US-			
		US-			
~ ~~~~		US-			
		US-			*
		US-			
		US-	•	·	
		US-			

			FOREIG	N PATENT DOC	IMENTS		
	miner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initia		No.'	Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
M	S		EP 0 253 500	02/27/1991	Imperial Chemical Ind		
1			EP 0 253 503	12/11/1991	Imperial Chemical Ind		
	1/	**********	GB 2 146 987 A	09/19/1984	Sandoz, Ltd.		
•	W		EP 0 154 528 A2	03/01/1985	Imperial Chemical Ind		
	MS		EP 0311447	12/04/1989	Farmos Yhtyma Oy		

Examiner Signature	/D Margaret Seaman/	Date Considered	05/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Sea Kinds Codes of USPTO Patent Documents at www.usr/to.nov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Transation is a stached.
This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiallity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

	Substitute for form 14494/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Named in Art Unit Evaminer Name	Application Number	10/739,208				
	INFORMATION D	ISCLOS	URE	Filing Date	December 18, 2003	
		First Named Inventor	KUZMICH, Daniel et al			
	OIA IEMENT DI	A L.O.		Art Unit	1614	739,208 ecember 18, 2003 UZMICH, Daniel et al 4 o be assigned
	(Use as many sheets	as necessary)		Examiner Name	To be assigned	
Sher	7	of	5_	Attorney Docket Number	9/272.	

Cuaminas	Ola-	Designant Number	U. S. PATENT D Publication Date	Name of Patentee or	Page Columns Lines Where
Examiner Initiats*	Cite No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
uniais -	NO.	Number-Kind Code ^{2 (F troom)}	111111111111111111111111111111111111111	Applicant of Cited Cocument	Figures Appear
		US-			
		US-	•		
		US-			
		US-			
		US-			***************************************

		FOREIG	N PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'NInd Code ³ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⊤ ⁴
MS		WO 96/19458	06/27/1996	Ligand Pharmaceut.		
1	1	WO 97/27852	08/07/1997	Merck & Company		
	 	WO 98/54159	12/03/1998	Schering Aktien.	•	
V	ļ <u>.</u>	WO 00/32584	06/08/2000	Scherin Aktien.		
MS	!	BE 900594	03/18/1985	Sandoz S.A.	C man and 11 to be seen to the man a base of the seen to the seen	

Examiner Signature	/D Margaret Seaman/	Date Considered	05/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usrto.cov or MPEP 901.04. 3 Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language

the appropriate symbols as indicated on the occurrent under wird statuting the appropriate symbols as indicated on the occurrent under wird statuting the property of the prop

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 14498/PTO			Complete If Known				
				Application Number	10/739,208			
INFO	RMATION DI	SCLO	SURE	Filing Date	December 18, 2003			
STAT	EMENT BY	APPLI	CANT	First Named Inventor	KUZMICH, D., et al			
				Art Unit	1614			
	(Use as many sheets at	necessary))	Examiner Name	To be Assigned			
Sheet	4	of	5	Attorney Docket Number	9/272			

include tailie of the dutal (in car i include tailie of the dutal cardes (when appropriate), the of the item (box)	T²
Hamann, Lawrence, et al; Discovery of a potent, Orally active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyrldono[5,6-gl-quinoline(LG12107l), J. Med Chem, 1999, 42, 210-212	
Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466	
Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem 1998, 41, 303-310	
Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41, 291-302	
Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class Of Nonsteroidal Progesterone Receptor Agonists: Effect of A-Ring Modification, J. Med. Chem 1999, 42, 1466-1472	
Tegley, Christopher, et al; 5-Benzylldene 1,2-Dlhydrochromeno[3,4-f]qulnolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359	
Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists: J. Med. Chem. 1998.41, 2779-2785	
Hamann, Lawrence, et al; Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g] guinolines J. Med. Chem 1998, 41, 623-639	
English Translation of WO/02/10143	-
	••••
	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Hamann, Lawrence, et al; Discovery of a potent, Orally active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-gl-quinoline(LG12107I), J. Med Chem, 1999, 42, 210-212 Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466 Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem 1998, 41, 303-310 Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41, 291-302 Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class Of Nonsteroidal Progesterone Receptor Agonists: Effect of A-Ring Modification, J. Med. Chem 1999, 42, 1466-1472 Tegley, Christopher, et al; 5-Benzylidene 1,2-Dihydrochromeno[3,4-f]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359 Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestigenone, Receptor Agonists; J. Med. Chem. 1998, 41, 2779-2785. Hamann, Lawrence, et al; Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g] gulnolines, J. Med. Chem. 1998, 41, 623-639.

Examiner	/D Margaret Seaman/	Date Considered	05/18/2006
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	te for form 14498/PTO			Complete If Known		
				Application Number	10/739,208	
INF	ORMATION D	SCLO	SURE	Filing Date	December 18, 2003	
ST	ATEMENT BY	APPLIC	CANT	First Named Inventor	KUZMICH, D., et al	
				Art Unit	1614	
	(Use as many sheets a	в песеввагу)		Examiner Name	To be Assigned	
Shee	5	of	5	Attorney Docket Number	9/272	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
MS		BEKKALI, Y., et al; Application entitled Glucocorticoid Mirnetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Serial No. 10/639,131					
MS		CYWIN, C. et al; Application entitled Glucocorticold Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Serial No. 10/785,222					
	14477774444						
à							
D	*** (** 090 9**** **						
<u></u>	- 20 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						
***	·····						

			<u> </u>
Examiner	/D Margaret Seaman/	Date	05/18/2006
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (06-03)

Approved for use through 07/31/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A/PTO	1993, no berso	ons are required to	respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
				Application Number	Fobe assigned 10/73920		
	INFORMATION D	SCLOS	SURE	Filing Date	December 18, 2003		
	STATEMENT BY	APPLIC	CANT	First Named Inventor	Kuzmich, Daniel et al		
				Art Unit	To be assigned		
	(Use as many sheets a	s necessary)	<u> </u>	Examiner Name	To be assigned		
Sher	1 1	of	4	Attorney Docket Number	9/272		

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f Incomp}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MS		^{US-} 6,323,199	11/27/2001	Lehmann, M. et al	
		^{US-} 5,039,691	08//13/1999	Spagnuolo, C. et al	
		^{US-} 6,583,180	06/24/2003	Link, J.T. et al	
		^{US-} 6,329,534	12/11/2001	Kym, P.R. et al	
		^{US-} 6,436,986	08/20/2003	Kym, P.R. et al	
		^{US-} 4,880,839	11/14/1999	Tucker, H.	
1		^{US-} 2002/0156311	10/24/2002	Link, J.T. et al	
V		^{US-} 6,506,766	01/14/2003	Coghlan, M.J. et al	
MS		^{US-} 6,380,223	04/30/2002	Dow, R.L., et al	
		US-			
		US-			
		US-			
		US-		-	
		US-			
		US-			
		U\$-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	No. 1 Country Code ³ Number ⁴ 'Kind Code ⁵ (# known) MI		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T*		
MS		WO 02/10143	02/07/2002	Schering Aktiengesel.				
1		WO 02064550	08/22/2002	Abbott Laboratories				
		WO 99/41256	02/12/1999	Abbott Laboratories				
V	******	WO 02/02565	01/10/2002	Abbott Laboratories	***************************************			
MS	************	WO 00/66522	11/09/2000	Pfizer Products, Inc	**************************************			

Examiner Date /D Margaret Seaman/ 05/18/2016 Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.usr/to.nov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Trainstation is associated.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449A/PTO			Complete if Known			
				Application Number	To be assigned 10/739208		
	INFORMATION DI	SCLO	SURE	Filing Date	December 18, 2003		
	STATEMENT BY	APPLI	CANT	First Named Inventor	KUZMICH, Daniel, et al		
	· · · · · · · · · · · · · · · · · · ·		•	Art Unit	To be assigned		
	(Use as many sheets as	necessary)		Examiner Name	To be assigned		
She	et 2	of	4	Attorney Docket Number	9/272		

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.'	Number-Kind Code ² (Fixom)	MM-DD-YYYY	Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
	-	US-	·····		
	 	US-			
	一	US-			
		US-			
 -		US-			·····
·····		UŞ-			· · · · · · · · · · · · · · · · · · ·
	 	US	<u> </u>		
		US-			
	 	U\$-			
	l	US-			
	\vdash	US-			
		US-			
		US-			
		US-			
		US-			
		US-			
	\vdash	US-	······		

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code ³ Number ⁴ 'Kind Code ⁵ (# known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ,		
MS		EP 0 253 500	02/27/1991	Imperial Chemical Ind	-			
1		EP 0 253 503	12/11/1991	Imperial Chemical Ind				
17.	**********	GB 2 146 987 A	09/19/1984	Sandoz, Ltd.				
V		EP 0 154 528 A2	03/01/1985	Imperial Chemical Ind				
MS	**********	EP 0 154 528 A3	03/01/1985	Imperial Chemical Ind				

Examiner Signature	/D Margaret Seaman/	Date Considered	05/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usrto.nov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Transation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (06-03)

Approved for use through 07/31/2003, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A/PTO			Complet if Known		
				Application Number	To be assigned 10/739208	
	INFORMATION D	SCLO	SURE	Filing Date	December 18, 2003	
	STATEMENT BY	APPLI	CANT	First Named Inventor	KUZMICH, Daniel et al	
				Art Unit	To be assigned	
	(Use as many sheets a	s necessary	,	Examiner Name	To be assigned	
She	eet 3	of	4	Attorney Docket Number	9/272	

	- i		U. S. PATENT		
Examiner initials*	Cite No.	Document Number Number-Kind Code ² (* taxons)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-		<u> </u>	
		US-			
**		US-			
-		US-			
		US	· · · ·		
		US-			
		US-			
		US-			**************************************
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*	No.1	Country Code ³ Number ⁴ 'RInd Code ⁵ (# known)	MM-DD-YYYY	Applicant of Cited Document		T*	
MS		WO 96/19458	06/27/1996	Ligand Pharmaceut.			
1		WO 97/27852	08/07/1997	Merck & Company			
		WO 98/54159	12/03/1998	Schering Aktien.	***************************************	Г	
V		WO 00/32584	06/08/2000	Scherin Aktien.	·		
MS		BE 900594	03/18/1985	Sandoz S.A.	•	Г	

Examiner		Date	05/10/0006
Signature	/D Margaret Seaman/	Considered	05/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Occuments at www.usrrio.nov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includiat case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	Lobe assigned 10/739208	
INFORMATION DISCLOSURE				Filing Date	December 18, 2003	
STATEMENT BY APPLICANT			CANT	First Named Inventor	Kuzmich, Daniel et al	
				Art Unit	To be assigned	
(Use as many sheets as necessary))	Examiner Name	To be assigned	
Sheet	4	of	4	Attorney Docket Number	9/272	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MS		Hamann, Lawrence, et al; Discovery of a potent, Orally active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-gl-quinoline(LG12107l), J. Med Chem, 1999, 42, 210-212	
MS		Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466	
MS		Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroldal Progestgerone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem 1998, 41, 303-310	
MS		Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41, 291-302	
MS		Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class Of Nonsteroidal Progesterone Receptor Agonists: Effect of A-Ring Modification, J. Med. Chem 1999, 42, 1466-1472	
MS		Tegley, Christopher, et al; 5-Benzylldene 1,2-Dihydrochromeno[3,4-f]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359	
MS		Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists: J. Med. Chem. 1998.41. 2779-2785	
MS		Hamann, Lawrence, et al; Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g] quinolinesJ. Med. Chem.1998.41.623-639	
		English Translation of WO/02/10143	
Muster	************	·	

ſ	Examiner	/D Margaret Seaman/	Date	05/18/2006	
l	Signature	/D Margaret Seaman/	Considered	05/18/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.